NovaBridge Biosciences (NBP) Liabilities and Shareholders Equity (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $260.5 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 22.49% year-over-year to $260.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $953.6 million (up 36.38% YoY) and the FY2025 annual result came in at $260.5 million, up 22.49% from the prior year.
• Liabilities and Shareholders Equity retreated to $260.5 million in Q4 2025 per NBP's latest filing, from $277.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NBP reached as high as $952.2 million in Q2 2021 and fell as low as $206.7 million in Q2 2025.
• A 5-year average of $435.6 million and a median of $277.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 228.37% — and 2024, when it tumbled 49.37%.
• Year by year, Liabilities and Shareholders Equity stood at $876.1 million in 2021, then sank by 34.62% to $572.8 million in 2022, then tumbled by 36.64% to $362.9 million in 2023, then plunged by 41.4% to $212.7 million in 2024, then rose by 22.49% to $260.5 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $260.5 million, $277.4 million, and $206.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.